JO3030B1 - مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات - Google Patents

مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات

Info

Publication number
JO3030B1
JO3030B1 JOP/2010/0179A JOP20100179A JO3030B1 JO 3030 B1 JO3030 B1 JO 3030B1 JO P20100179 A JOP20100179 A JO P20100179A JO 3030 B1 JO3030 B1 JO 3030B1
Authority
JO
Jordan
Prior art keywords
treatment
degenerative
inflammatory diseases
diseases
novel compound
Prior art date
Application number
JOP/2010/0179A
Other languages
English (en)
Inventor
Blanc Javier
Jeanne Marie Menet Christel
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Application granted granted Critical
Publication of JO3030B1 publication Critical patent/JO3030B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يتم الإفصاح عن أي مركب يحتوي على الصيغة التي يمثلها على النحو التالي: يمكن تحضير المركب الحالي كتوليفة صيدلانية ويمكن إستخدامه للوقاية والعلاج من الحالات المختلفة في الثدييات بما فيها البشر والمشتملة على أمثلة غير مقصورة على حالات الإلتهابات أو أمراض المناعة الذاتية أو أمراض التكاثري أو رفض الزراعة أو الأمراض المشتملة على تلف دوران الغضروف أو تشوهات الغضروف الخلقي و/أو الأمراض المصاحبة لفَرْطُ إِفْراز IL6.
JOP/2010/0179A 2009-06-26 2010-05-31 مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات JO3030B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22068509P 2009-06-26 2009-06-26
US29818810P 2010-01-25 2010-01-25

Publications (1)

Publication Number Publication Date
JO3030B1 true JO3030B1 (ar) 2016-09-05

Family

ID=42340530

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0179A JO3030B1 (ar) 2009-06-26 2010-05-31 مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات

Country Status (38)

Country Link
US (2) US8796457B2 (ar)
EP (2) EP2445912B1 (ar)
JP (1) JP5486084B2 (ar)
KR (1) KR101712561B1 (ar)
CN (1) CN102459261B (ar)
AR (1) AR077221A1 (ar)
AU (1) AU2010264635B2 (ar)
BR (1) BRPI1014759A2 (ar)
CA (1) CA2765988C (ar)
CL (1) CL2011003276A1 (ar)
CO (1) CO6491039A2 (ar)
CR (1) CR20110673A (ar)
CY (1) CY1119711T1 (ar)
DK (2) DK2792677T3 (ar)
DO (1) DOP2011000378A (ar)
EA (1) EA020111B1 (ar)
ES (2) ES2519170T3 (ar)
HK (2) HK1202537A1 (ar)
HR (2) HRP20141057T1 (ar)
HU (1) HUE034205T2 (ar)
IL (1) IL216618A (ar)
JO (1) JO3030B1 (ar)
LT (1) LT2792677T (ar)
MA (1) MA33447B1 (ar)
ME (1) ME01916B (ar)
MX (1) MX2011013451A (ar)
NZ (1) NZ596836A (ar)
PE (1) PE20120494A1 (ar)
PL (2) PL2792677T3 (ar)
PT (2) PT2445912E (ar)
RS (1) RS53617B1 (ar)
SG (1) SG177359A1 (ar)
SI (2) SI2445912T1 (ar)
SM (1) SMT201400169B (ar)
TW (1) TWI469981B (ar)
UY (1) UY32741A (ar)
WO (1) WO2010149771A1 (ar)
ZA (1) ZA201109502B (ar)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
CA2832611C (en) 2011-04-12 2019-05-14 Rigel Pharmaceuticals, Inc. Methods for inhibiting allograft rejection
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
SG10201914052TA (en) * 2011-10-11 2020-03-30 Sanofi Biotechnology Compositions for the treatment of rheumatoid arthritis and methods of using same
SG10201700125VA (en) * 2012-06-22 2017-02-27 Galapagos Nv Aminotriazolopyridine For Use In The Treatment Of Inflammation, And Pharmaceutical Compositions Thereof
MX2016002764A (es) 2013-09-05 2016-05-26 Hoffmann La Roche Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos.
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EA037911B1 (ru) * 2015-04-13 2021-06-04 Галапагос Нв Способы лечения сердечно-сосудистых заболеваний
US11279699B2 (en) 2016-07-26 2022-03-22 Suzhou Longbiotech Pharmaceuticals Co., Ltd. Compound as selective JAK inhibitor, and salt and therapeutic use thereof
US11427581B2 (en) 2018-01-31 2022-08-30 Zhuhai United Laboratories Co., Ltd. JAK inhibitor and use thereof
CA3110891A1 (en) 2018-08-29 2020-03-05 Regeneron Pharmaceuticals, Inc. Methods and compositions for treating subjects having rheumatoid arthritis
US11498969B2 (en) 2019-01-31 2022-11-15 Sanofi Biotechnology Compositions and methods for treating juvenile idiopathic arthritis
CN111072655B (zh) * 2019-12-30 2021-12-10 深圳市坤健创新药物研究院 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用
EP4153564A4 (en) 2020-05-19 2024-06-19 Cybin IRL Limited DEUTERATED TRYPTAMINE DERIVATIVES AND METHODS OF USE
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4058243B2 (ja) 1999-01-29 2008-03-05 中外製薬株式会社 軟骨形成促進剤およびインドリン−２−オン誘導体
US20040138285A1 (en) 2001-04-27 2004-07-15 Makoto Okazaki Chondrogenesis promoters
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
AU2003231880A1 (en) * 2002-05-30 2003-12-19 Vertex Pharmaceuticals Incorporated Inhibitors of jak and cdk2 protein kinases
DE602004001676T2 (de) 2003-02-14 2007-08-30 Pfizer Products Inc., Groton Triazolo-Pyridine als entzündungshemmende Verbindungen
US20050222171A1 (en) * 2004-01-22 2005-10-06 Guido Bold Organic compounds
ES2427136T3 (es) 2004-06-21 2013-10-29 Galapagos N.V. Métodos y medios para el tratamiento de la osteoartritis
JP2008509987A (ja) 2004-08-18 2008-04-03 ファルマシア アンド アップジョン カンパニー リミテッド ライアビリティ カンパニー トリアゾロピリジン化合物
JP2008515874A (ja) 2004-10-07 2008-05-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 抗菌薬
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
BRPI0716239A2 (pt) * 2006-08-30 2013-08-13 Cellzome Ltd derivados de triazol como inibidores de cinase
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
CN101801966A (zh) 2007-07-18 2010-08-11 诺瓦提斯公司 双环杂芳基化合物和它们作为激酶抑制剂的用途
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
EP2181112A1 (en) 2007-08-31 2010-05-05 Merck Serono S.A. Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
US20090217316A1 (en) * 2008-02-22 2009-08-27 Binita Gupta Systems and Methods for Advertising Insertion Notification in a Real-Time Streaming Media Service
JP5595389B2 (ja) 2008-06-20 2014-09-24 ジェネンテック， インコーポレイテッド トリアゾロピリジンｊａｋ阻害剤化合物と方法
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010186A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
EP2438066A2 (en) 2009-06-05 2012-04-11 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物

Also Published As

Publication number Publication date
TW201103937A (en) 2011-02-01
MA33447B1 (ar) 2012-07-03
NZ596836A (en) 2013-02-22
DOP2011000378A (es) 2012-02-15
ME01916B (me) 2015-05-20
JP2012530767A (ja) 2012-12-06
JP5486084B2 (ja) 2014-05-07
RS53617B1 (en) 2015-04-30
WO2010149771A1 (en) 2010-12-29
HRP20171024T1 (hr) 2017-10-06
EA020111B1 (ru) 2014-08-29
ES2634325T3 (es) 2017-09-27
CA2765988C (en) 2017-08-29
CN102459261B (zh) 2014-11-05
US20150031671A1 (en) 2015-01-29
CL2011003276A1 (es) 2012-08-31
AU2010264635B2 (en) 2015-05-07
KR20120059487A (ko) 2012-06-08
PE20120494A1 (es) 2012-05-17
EP2792677A1 (en) 2014-10-22
ES2519170T3 (es) 2014-11-06
CO6491039A2 (es) 2012-07-31
CY1119711T1 (el) 2018-06-27
SI2792677T1 (sl) 2017-08-31
AU2010264635A1 (en) 2011-12-22
HRP20141057T1 (en) 2015-03-13
CR20110673A (es) 2012-02-09
UY32741A (es) 2011-01-31
KR101712561B1 (ko) 2017-03-06
BRPI1014759A2 (pt) 2016-04-19
HK1168098A1 (en) 2012-12-21
SMT201400169B (it) 2015-01-15
ZA201109502B (en) 2012-09-26
LT2792677T (lt) 2017-07-25
SG177359A1 (en) 2012-02-28
EP2445912B1 (en) 2014-08-13
PT2792677T (pt) 2017-07-06
AR077221A1 (es) 2011-08-10
IL216618A0 (en) 2012-02-29
EP2445912A1 (en) 2012-05-02
IL216618A (en) 2014-09-30
DK2445912T3 (da) 2014-11-10
EP2792677B1 (en) 2017-04-26
PT2445912E (pt) 2014-11-07
MX2011013451A (es) 2012-04-30
HUE034205T2 (en) 2018-01-29
EA201270076A1 (ru) 2012-08-30
TWI469981B (zh) 2015-01-21
US20100331359A1 (en) 2010-12-30
CA2765988A1 (en) 2010-12-29
HK1202537A1 (en) 2015-10-02
US8796457B2 (en) 2014-08-05
CN102459261A (zh) 2012-05-16
US9505754B2 (en) 2016-11-29
SI2445912T1 (sl) 2014-12-31
PL2445912T3 (pl) 2015-02-27
PL2792677T3 (pl) 2017-09-29
DK2792677T3 (en) 2017-07-10

Similar Documents

Publication Publication Date Title
JO3030B1 (ar) مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
MX2013012281A (es) Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias.
MY156664A (en) 5-phenyl-[1, 2, 4]triazolo[1, 5-a]pyridin-2-yl carboxamides as jak inhibitors
PH12014502615B1 (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
MY150542A (en) Cmet inhibitors
GB201013307D0 (en) Anti-microbial metal organic framework
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
IN2012DN03883A (ar)
GB201213267D0 (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
WO2011091322A3 (en) Antimicrobial agent comprising peroxide, alcohol and chelating agent
TW201613873A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MX2012004780A (es) Inhibidores de akt.
WO2011041311A3 (en) Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods
MX2012004282A (es) Composiciones farmaceuticas.
UA105796C2 (uk) Сполука, застосовна для лікування дегенеративних і запальних захворювань
CY1115695T1 (el) Νεα ενωση χρησιμη για τη θεραπεια εκφυλιστικων και φλεγμονωδων ασθενειων
TN2011000020A1 (en) cMET INHIBITORS
MY182136A (en) Pharmaceutical compositions
TN2010000583A1 (en) Organic compounds
TN2010000527A1 (en) Glucokinase activators